The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Magrolimab + azacitidine in TP53-mutant AML
David Sallman, MD, Moffit Cancer Center, Tampa, FL, shares the findings of a Phase Ib study investigating the combination of magrolimab and azacitidine in patients with TP53-mutant acute myeloid leukemia (AML) (NCT03248479), commenting on the tolerability and efficacy of this combination in this high-risk patient group. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Incyte: Speakers Bureau; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Agios: Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy.
